Company Quick10K Filing
Jamba
10-Q 2018-07-03 Filed 2018-08-13
10-Q 2018-04-03 Filed 2018-06-26
10-K 2018-01-02 Filed 2018-05-11
10-Q 2017-10-03 Filed 2018-03-15
10-Q 2017-07-04 Filed 2018-03-15
10-Q 2017-04-04 Filed 2018-03-15
10-K 2017-01-03 Filed 2018-02-12
10-Q 2016-09-27 Filed 2016-11-07
10-Q 2016-06-28 Filed 2016-08-05
10-Q 2016-03-29 Filed 2016-05-06
10-K 2015-12-29 Filed 2016-03-14
10-Q 2015-09-29 Filed 2015-11-09
10-Q 2015-06-30 Filed 2015-08-10
10-Q 2015-03-31 Filed 2015-05-11
10-K 2014-12-30 Filed 2015-03-30
10-Q 2014-09-30 Filed 2014-11-07
10-Q 2014-07-01 Filed 2014-08-11
10-Q 2014-04-01 Filed 2014-05-09
10-K 2013-12-31 Filed 2014-03-10
10-Q 2013-10-01 Filed 2013-11-06
10-Q 2013-04-02 Filed 2013-05-02
10-K 2013-01-01 Filed 2013-03-07
10-Q 2012-10-02 Filed 2012-11-05
10-Q 2012-07-03 Filed 2012-08-02
10-Q 2012-04-03 Filed 2012-05-08
10-K 2012-01-03 Filed 2012-03-09
10-Q 2011-10-04 Filed 2011-11-10
10-Q 2011-07-12 Filed 2011-08-17
10-Q 2011-04-19 Filed 2011-05-24
10-K 2010-12-28 Filed 2011-03-14
10-Q 2010-10-05 Filed 2010-11-10
10-Q 2010-07-13 Filed 2010-08-19
10-Q 2010-04-20 Filed 2010-05-27
10-K 2009-12-29 Filed 2010-03-10
8-K 2018-09-13
8-K 2018-08-13
8-K 2018-08-01
8-K 2018-06-26
8-K 2018-06-26
8-K 2018-05-15
8-K 2018-05-11
8-K 2018-04-04
8-K 2018-03-20
8-K 2018-03-15
8-K 2018-02-12
8-K 2018-02-12
8-K 2018-01-02
8-K 2018-01-02

Jamba Financials

JMBA Metrics, Comps, Filings

Quarterly | Annual

Valuation ($BB)

Market Cap, Enterprise Value

Balance Sheet ($BB)

Assets, Equity

Income Statement ($BB Quarterly)

Revenue, G Profit, Net Income

Cash Flow ($BB Quarterly)

Ops, Inv, Fin

Comps ($MM TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Energy & Technology (ENGT) 177 32% -1,446.0 -4% 4 9 3 1 -0 -0 177
Kraig Biocraft Laboratories (KBLB) 176 -99.2 -224% 1 6 0 0 -2 -2 176
American BriVision (ABVC) 175 97% -71.6 -38% 7 7 1 1 -3 -2 174
Vaneck Merk Gold Trust (OUNZ) 175 8.4 12% 175 0 0 0 21 21 175
Invesco DB Gold Fund (DGL) 174 9.8 10% 174 4 0 0 18 18 174
Fulcrum Therapeutics (FULC) 173 -2.4 -26% 116 14 0 0 -30 -30 71
MariMed (MRMD) 172 39% 23.2 -2% 137 54 40 16 -2 9 212
Fortem Resources (FTMR) 191 -119.9 -1% 143 19 0 0 -2 -2 192
Cure Pharmaceutical (CURR) 171 94% -10.1 -60% 34 21 0 0 -20 -16 166
FC Global Realty (FCRE) 171 86% -62.4 -2% 134 53 0 0 -3 -3 171
Applied Therapeutics (APLT) 170 -5.6 -75% 37 7 0 0 -28 -28 157
SWK Holdings (SWKH) 167 0% 9.7 6% 248 20 21 0 15 17 163
DOCASA (DCSA) 167 24% -117.8 -8% 22 7 6 2 -2 -1 166
Jamba (JMBA) 165 0% 68.1 -4% 37 47 78 0 -2 2 156
QNB (QNBC) 162 5.6 1% 1,246 1,127 0 0 12 25 141
Diverse Development Group (DDG) 161 -3,433.4 -24,302% 0 0 0 0 -0 -0 161
Gold Reserve (GDRZF) 161 -8.9 -15% 78 104 0 0 -12 -12 103
Blackstar Enterprise Group (BEGI) 156 -313.5 -13,158% 0 0 0 0 -0 -0 156
Invesco CurrencyShares British Pound Sterling Trust (FXB) 156 0% -5.1 -0% 155 0 0 0 -0 -0 0
Northwest Indiana Bancorp (NWIN) 154 4.5 1% 1,330 1,197 0 0 10 18 82

Balance Sheet ($MM)2011-07-122011-10-042012-01-032012-04-032012-07-032012-10-022013-01-012013-04-022013-06-302013-10-012013-12-312014-04-012014-07-012014-09-302014-12-302015-03-312015-06-302015-09-292015-12-292016-03-292016-06-282016-09-272017-01-032017-04-042017-07-042017-10-032018-01-022018-04-032018-07-03
Cash22252019293231233329322532301881425201316147811121089
Accounts Receivable7813986118871413151217161918171612121291071099
Inventory232233334333232221
PP&E474645424039108384040107384040791614135618181951121111441010
Assets889188828889948293899892105100928082757059565642394038413537
Accounts Payable764667847455544211422233
Long-Term Debt
Liabilities6361686365617261655771656965767167636556555655565452554647
Stockholders' Equity81221520141928322728353517915135-17-14
Income Statement ($MM)2011-07-122011-10-042012-01-032012-04-032012-07-032012-10-022013-01-012013-04-022013-06-302013-10-012013-12-312014-04-012014-07-012014-09-302014-12-302015-03-312015-06-302015-09-292015-12-292016-03-292016-06-282016-09-272017-01-032017-04-042017-07-042017-10-032018-01-022018-04-032018-07-03
Revenue5957425366654455676144526458445354352019222217182118152124
Cost of Revenue
Gross Profit
R&D
SG&A87129111012910810810910989108910119776811
Tax-0000000001-100-00000-00-0-000-00000
Net Income44-10-254-7-163-6-06-2-8-2613-8-3-2-2-15-32-0-10-0
Cash Flow ($MM)2011-07-122011-10-042012-01-032012-04-032012-07-032012-10-022013-01-012013-04-022013-06-302013-10-012013-12-312014-04-012014-07-012014-09-302014-12-302015-03-312015-06-302015-09-292015-12-292016-03-292016-06-282016-09-272017-01-032017-04-042017-07-042017-10-032018-01-022018-04-032018-07-03
Cash Operating6-411151-613-1-512-1-2-50-6-4-640-511-1-22
Cash Investing-3-1-1-1-2-1-3-4-3-3-5-1-02833-1-1-1-2-3-0-1-1-1-0
Cash Financing-0-0-0-0-0-000-0011-10-6-3-16-1000000-0